DexCom Inc (DXCM.OQ)
72.74USD
19 Apr 2018
$-0.76 (-1.03%)
$73.50
$73.31
$73.49
$72.29
224,522
396,625
$81.81
$42.63
Latest Key Developments (Source: Significant Developments)
DexCom Says Preliminary Q4 Revenue Was $218 Mln
Jan 8 (Reuters) - DexCom Inc
Dexcom announces development agreement with Lilly
Nov 21 (Reuters) - Dexcom Inc
Dexcom Inc reports Q3 GAAP loss per share $0.02
Nov 1 (Reuters) - Dexcom Inc
Tandem Diabetes Care to provide all t:slim X2 insulin pump features approved in 2018 to users at no cost
Oct 24 (Reuters) - Tandem Diabetes Care Inc
Janus Henderson reports 10.2 pct passive stake in Dexcom
Oct 11 (Reuters) - Janus Henderson Group PLC:Janus Henderson Group PLC reports a 10.2 percent passive stake in Dexcom Inc as of sept 30 - SEC filing. Full Article
Dexcom Inc Reports second quarter 2016 financial results
Dexcom Inc
Dexcom Inc says FDA posts briefing documents ahead of advisory committee meeting
Dexcom Inc
Dexcom to expand manufacturing operations to Greater Phoenix
Dexcom Inc
Dexcom says entered into $200 mln revolving credit agreement
Dexcom Inc : On june 17, entered into $200 million revolving credit agreement with jpmorgan chase bank, n.a., bank of america, silicon valley bank,union bank . Says as Of June 17, 2016, Dexcom had no outstanding loans under credit agreement - Sec filing . Credit agreement provides a subfacility of up to $10 million for letters of credit . Dexcom inc says credit agreement matures on june 17, 2021 . Credit agreement provides a $25 million sublimit for borrowings in canadian dollars, euros, british pounds, swedish krona, japanese yen .Has option to increase maximum principal amount available under credit agreement by up to an additional $100 million. Full Article
BRIEF-FDA Authorizes Marketing Of New Dexcom G6 CGM Eliminating Need For Fingerstick Blood Testing
* FDA AUTHORIZES MARKETING OF THE NEW DEXCOM G6® CGM ELIMINATING NEED FOR FINGERSTICK BLOOD TESTING FOR PEOPLE WITH DIABETES
Earnings vs. 
Estimates